IRAK4-IN-1 NEW
| Price | $64 | $155 | $239 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: IRAK4-IN-1 | CAS No.: 1820787-94-7 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | IRAK4-IN-1 |
| Description | IRAK4-IN-1 is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. |
| Animal Research | In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured. |
| In vitro | The in vitro metabolic stability profile of IRAK4-IN-1 was assessed, yielding an EC50 of 2300 nM in rat whole blood (RWB). |
| In vivo | Oral pharmacokinetic analyses of IRAK4-IN-1 indicate that it possesses a high bioavailability of 73%, along with low plasma clearance (Clp=22 mL/min/kg), which culminates in a stable half-life of 1.3 hours. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 1 mg/ml, Sonication is recommended. H2O : < 0.1 mg/mL (insoluble) |
| Keywords | IRAK4-IN-1 | inhibit | IRAK4 IN 1 | Inhibitor | IL-1R associated kinase | Interleukin-1 receptor associated kinase | IRAK4IN1 | IRAK-4-IN-1 | IRAK |
| Inhibitors Related | IRAK inhibitor 2 | IRAK inhibitor 1 | IRAK-1-4 Inhibitor I | IRAK-4 protein kinase inhibitor 2 | ANTHRAQUINONE-2-CARBOXYLIC ACID | Thalidomide 4-fluoride | IRAK4-IN-20 | GLPG2534 | Zabedosertib | Zimlovisertib | AS-2444697 | JH-X-119-01 |
| Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-Liver Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $58.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $1820.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/10mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-10-29 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY